Home » Topics » Regulatory » EMA

EMA
RSS

Novo Nordisk withdraws E.U. application to expand repaglinide product labels

Oct. 18, 2006

Withdrawal of E.U. marketing authorization for Fortovase

Aug. 14, 2006

Negative opinion handed down for Valdoxan/Thymanax in Europe

Aug. 3, 2006

Positive opinion handed down in Europe for Ganfort

March 28, 2006

Alcon withdraws European submission for Retaane

March 3, 2006

Alcon withdraws application to extend European approval of Opatanol

Feb. 28, 2006

February meeting of European Committee for Orphan Medicinal Products

Feb. 18, 2005

Positive opinion for new Thyrogen indication in Europe

Jan. 27, 2005

EMEA warns on new safety findings for valdecoxib, parecoxib sodium

Dec. 27, 2004

EMEA warns on coadministration of Reyataz and Norvir with omeprazole

Dec. 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...